AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

AstraZeneca PLC (LON:AZN) has been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is £152.17.

A number of research firms have recently weighed in on AZN. Berenberg Bank reiterated a “buy” rating and set a £160 price target on shares of AstraZeneca in a report on Tuesday, July 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a £175 target price on shares of AstraZeneca in a research report on Monday, August 3rd. Citigroup increased their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and set a £115 price target on shares of AstraZeneca in a research report on Wednesday, August 5th.

AstraZeneca Price Performance

AZN stock opened at £114.60 on Friday. AstraZeneca has a 52-week low of £107.84 and a 52-week high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The stock has a market cap of £177.73 billion, a price-to-earnings ratio of 17.16, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The business has a fifty day moving average of £130.25 and a two-hundred day moving average of £138.79.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.